# Aomingcheng (Shenzhen) Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aomingcheng-shenzhen-biotechnology-co

- Industry: Healthcare
- Headquarters: Shenzhen, China
- Total disclosed funding: $15M
- Latest round: Series A (Apr 24, 2026)
- Investors on record: 5

## About

Based in Shenzhen, China and founded in 2021, Aomingcheng (Shenzhen) Biotechnology Co., Ltd. focuses on developing a proprietary "Data-Large Model-Agent" ecosystem to revolutionize life sciences through advanced AI-driven research and clinical applications. In April 2026, Aomingcheng (Shenzhen) Biotechnology Co., Ltd. raised over CNY 100 million in Series A funding from Shenzhen Capital Real Estate Fund, Fosun Health Capital, Taiping Financial Holdings, Kaiheng Capital and Hangshi Group, with participation from other investors.
The company provides a comprehensive matrix of intelligent agents and diagnostic solutions, such as the OS-TuFEst® multi-cancer screening platform, which leverages cfDNA fragmentomics and AI models to deliver high-sensitivity early disease detection, drug R&D support, and personalized health management. 
The company generates revenue by providing clinical diagnostic services to hospitals and physical examination centers, collaborating with pharmaceutical companies on drug discovery, and licensing its AI4S platform capabilities.
The Series A funding raised in April 2026 will be used to build bio-intelligence infrastructure.
In the future, the company will focus on breakthroughs in three areas: First, enabling AI to move from "representation learning" to "mechanism modeling", not just predicting results, but approximating the intrinsic logic of disease development; second, equipping AI with "problem-defining capabilities", enabling it not only to answer questions but also to identify key variables in complex systems, assisting in formulating more valuable scientific questions; and third, developing AI's "exploratory reasoning capabilities", supporting an integrated research process from hypothesis generation to path deduction. In the long term, this system is expected to extend into "medical AGI" covering the entire life process.

## Funding rounds

- Series A, Apr 24, 2026, $15M — Shenzhen Capital Real Estate Fund, Taiping Financial Holdings, Hangshi Group, Fosun Health Capital, Kaiheng Capital

## Investors

- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Taiping Financial Holdings — Series A
- Hangshi Group (https://capitalatlas.ai/funds/hangshi-group) — Series A
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series A
- Kaiheng Capital (https://capitalatlas.ai/funds/kaiheng-capital) — Series A